The trimeric envelope glycoproteins (Env) on the surface of HIV-1 virions are the targets for neutralizing antibodies (NAbs). No candidate HIV-1 immunogen has yet induced potent, broadly active NAbs (bNAbs). Part of the explanation may be that previously tested Env proteins inadequately mimic the functional, native Env complex. Trimerization and the proteolytic processing of Env precursors into gp120 and gp41 profoundly alter antigenicity, but soluble cleaved trimers are too unstable to serve as immunogens. By introducing stabilizing mutations (SOSIP), we constructed soluble, cleaved Env trimers derived from the HIV-1 subtype A isolate BG505 that resemble native Env spikes on virions both structurally and antigenically. We used surface plas...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
The HIV-1 envelope glycoprotein (Env) trimer is located on the surface of the virus and is the targe...
An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV-1 antibo...
Background: The trimeric envelope glycoproteins (Env) on the surface of HIV-1 virions are the target...
<div><p>A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) ...
A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) vaccine ...
International audienceThe recent identification of three broadly neutralizing antibodies (bnAbs) aga...
International audienceThe recent identification of three broadly neutralizing antibodies (bnAbs) aga...
International audienceThe recent identification of three broadly neutralizing antibodies (bnAbs) aga...
International audienceThe recent identification of three broadly neutralizing antibodies (bnAbs) aga...
HIV-1 has evolved various tricks to prevent the development of a potent humoral immune response. The...
The recent identification of three broadly neutralizing antibodies (bnAbs) against gp120–gp41 interf...
HIV-1 envelope glycoproteins (Env) and Env-based immunogens usually do not interact efficiently with...
The HIV-1 envelope glycoprotein (Env) trimer is located on the surface of the virus and is the targe...
The HIV-1 envelope glycoprotein (Env) trimer is located on the surface of the virus and is the targe...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
The HIV-1 envelope glycoprotein (Env) trimer is located on the surface of the virus and is the targe...
An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV-1 antibo...
Background: The trimeric envelope glycoproteins (Env) on the surface of HIV-1 virions are the target...
<div><p>A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) ...
A desirable but as yet unachieved property of a human immunodeficiency virus type 1 (HIV-1) vaccine ...
International audienceThe recent identification of three broadly neutralizing antibodies (bnAbs) aga...
International audienceThe recent identification of three broadly neutralizing antibodies (bnAbs) aga...
International audienceThe recent identification of three broadly neutralizing antibodies (bnAbs) aga...
International audienceThe recent identification of three broadly neutralizing antibodies (bnAbs) aga...
HIV-1 has evolved various tricks to prevent the development of a potent humoral immune response. The...
The recent identification of three broadly neutralizing antibodies (bnAbs) against gp120–gp41 interf...
HIV-1 envelope glycoproteins (Env) and Env-based immunogens usually do not interact efficiently with...
The HIV-1 envelope glycoprotein (Env) trimer is located on the surface of the virus and is the targe...
The HIV-1 envelope glycoprotein (Env) trimer is located on the surface of the virus and is the targe...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
The HIV-1 envelope glycoprotein (Env) trimer is located on the surface of the virus and is the targe...
An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV-1 antibo...